Systems biology of JAK-STAT signalling in human malignancies

Progress in Biophysics and Molecular Biology

Volumn 106, Issue 2, 2011, Pages 426-434

  Vera, Julio ^a   Rateitschak, Katja ^a   Lange, Falko ^a   Kossow, Christina ^a   Wolkenhauer, Olaf ^a   Jaster, Robert ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Cell signalling; Interferon ; JAK STAT; Mathematical modelling; Pancreatic stellate cell; STAT1

Indexed keywords

GAMMA INTERFERON; JANUS KINASE; STAT PROTEIN;

ENZYMOLOGY; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; PANCREATIC STELLATE CELL; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

HUMANS; INTERFERON-GAMMA; JANUS KINASES; NEOPLASMS; PANCREATIC STELLATE CELLS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; SYSTEMS BIOLOGY;

EID: 80051672211     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2011.06.013     Document Type: Review

References (57)

1. Adimy M., Crauste F., Ruan S. Modelling hematopoiesis mediated by growth factors with applications to periodic hematological diseases. Bull. Math. Biol. 2006, 68:2321-2351.
2. Apte M., Pirola R., Wilson J. New insights into alcoholic pancreatitis and pancreatic cancer. J. Gastroenterol. Hepatol. 2009, 24(Suppl. 3):S51-S56.
3. Battle T.E., Frank D.A. The role of STATs in apoptosis. Curr. Mol. Med. 2002, 2:381-392.
4. Becker V., Schilling M., Bachmann J., Baumann U., Raue A., Maiwald T., Timmer J., Klingmüller U. Covering a broad dynamic range: information processing at the erythropoietin receptor. Science 2010, 328(5984):1404-1408.
5. Bernard S., Pujo-Menjouet L., Mackey M.C. Analysis of cell kinetics using a cell division marker: mathematical modeling of experimental data. Biophys. J. 2003, 84:3414-3424.
6. Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest. 2002, 109:1139-1142.
7. Bruns H.A., Kaplan M.H. The role of constitutively active Stat6 in leukemia and lymphoma. Crit. Rev. Oncol. Hematol. 2006, 57:245-253.
8. Colijn C., Mackey M.C. A mathematical model of hematopoiesis-I. Periodic chronic myelogenous leukemia. J. Theor. Biol. 2005, 237:117-132.
9. Colijn C., Mackey M.C. A mathematical model of hematopoiesis: II. Cyclical neutropenia. J. Theor. Biol. 2005, 237:133-146.
10. Constantinescu S.N., Girardot M., Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem. Sci. 2008, 33:122-131.
11. de Vos A.M., Ultsch M., Kossiakoff A.A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992, 255:306-312.
12. Finley S.D., Gupta D., Cheng N., Klinke D.J. Inferring relevant control mechanisms for interleukin-12 signaling in naïve CD4+ T cells. Immunol. Cell Biol. 2011, 89:100-110.
13. Flex E., Petrangeli V., Stella L., Chiaretti S., Hornakova T., Knoops L., Ariola C., Fodale V., Clappier E., Paoloni F., Martinelli S., Fragale A., Sanchez M., Tavolaro S., Messina M., Cazzaniga G., Camera A., Pizzolo G., Tornesello A., Vignetti M., Battistini A., Cavé H., Gelb B.D., Renauld J.C., Biondi A., Constantinescu S.N., Foà R., Tartaglia M. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J. Exp. Med. 2008, 205:751-758.
14. Harrison D.A., Binari R., Nahreini T.S., Gilman M., Perrimon N. Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J. 1995, 14:2857-2865.
15. Hayashi T., Kobayashi Y., Kohsaka S., Sano K. The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2. Oncogene 2006, 25:4016-4026.
16. Iadevaia S., Lu Y., Morales F., Mills G.B., Ram P.T. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational analysis. Cancer Res. 2010, [Epub ahead of print]. 10.1158/0008-5472.CAN-10-0460.
17. James C., Ugo V., Le Couédic J.P., Staerk J., Delhommeau F., Lacout C., Garçon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
18. Jaster R., Emmrich J. Crucial role of fibrogenesis in pancreatic diseases. Best Pract. Res. Clin. Gastroenterol. 2008, 22:17-29.
19. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
20. Lai X., Nikolov S., Wolkenhauer O., Vera J. A multi-level model accounting for the effects of JAK2-STAT5 signal modulation in erythropoiesis. Comput. Biol. Chem. 2009, 33:312-324.
21. Lange F., Rateitschak K., Fitzner B., Pöhland R., Wolkenhauer O., Jaster R. Studies on mechanisms of interferon-gamma action in pancreatic cancer using a data-driven and model-based approach. Mol. Cancer 2011, 10:13.
22. Levine R.L., Wernig G. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematol. Am. Soc. Hematol. Educ. Program 2006, 510:233-239.
23. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell. Biol. 2002, 3:651-662.
24. Li W.X. Canonical and non-canonical JAK-STAT signaling. Trends Cell. Biol. 2008, 18:545-551.
25. Lin T.S., Mahajan S., Frank D.A. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000, 19:2496-2504.
26. Livnah O., Stura E.A., Middleton S.A., Johnson D.L., Jolliffe L.K., Wilson I.A. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999, 283:987-990.
27. Luo H., Hanratty W.P., Dearolf C.R. An amino acid substitution in the Drosophila hopTum-l Jak kinase causes leukemia-like hematopoietic defects. EMBO J. 1995, 14:1412-1420.
28. Luo H., Rose P., Barber D., Hanratty W.P., Lee S., Roberts T.M., D'Andrea A.D., Dearolf C.R. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol. Cell. Biol. 1997, 17:1562-1571.
29. Mackey M.C. Unified hypothesis for the origin of aplastic anemia and periodic hematopoiesis. Blood 1978, 51:941-956.
30. Mahaffy J.M., Bélair J., Mackey M.C. Hematopoietic model with moving boundary condition and state dependent delay: applications in erythropoiesis. J. Theor. Biol. 1998, 190:135-146.
31. Mayya V., Loew L.M. STAT module can function as a biphasic amplitude filter. Syst. Biol. 2005, 2:43-52.
32. Melzner I., Bucur A.J., Brüderlein S., Dorsch K., Hasel C., Barth T.F., Leithäuser F., Möller P. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005, 105:2535-2542.
33. Meraz M.A., White J.M., Sheehan K.C., Bach E.A., Rodig S.J., Dighe A.S., Kaplan D.H., Riley J.K., Greenlund A.C., Campbell D., Carver-Moore K., DuBois R.N., Clark R., Aguet M., Schreiber R.D. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996, 84:431-442.
34. Moya C., Huang Z., Cheng P., Jayaraman A., Hahn J. Investigation of IL-6 and IL-10 signalling via mathematical modelling. IET Syst. Biol. 2011, 5(1):15.
35. Niwa Y., Kanda H., Shikauchi Y., Saiura A., Matsubara K., Kitagawa T., Yamamoto J., Kubo T., Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005, 24:6406-6417.
36. Pujo-Menjouet L., Mackey M.C. Contribution to the study of periodic chronic myelogenous leukemia. C. R. Biol. 2004, 327:235-244.
37. Raia V., Schilling M., Böhm M., Hahn B., Kowarsch A., Raue A., Sticht C., Bohl S., Saile M., Möller P., Gretz N., Timmer J., Theis F., Lehmann W.D., Lichter P., Klingmüller U. Dynamic mathematical modeling of IL13-induced signaling in Hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets. Cancer Res. 2011, 71(3):693-704.
38. Rateitschak K., Karger A., Fitzner B., Lange F., Wolkenhauer O., Jaster R. Mathematical modelling of interferon-gamma signalling in pancreatic stellate cells reflects and predicts the dynamics of STAT1 pathway activity. Cell. Signal. 2010, 22:97-105.
39. Rateitschak K., Wolkenhauer O. Intracellular delay limits cyclic changes in gene expression. Math. Biosci. 2007, 205:163-179.
40. Raue A., Kreutz C., Maiwald T., Bachmann J., Schilling M., Klingmüller U., Timmer J. Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood. Bioinformatics 2009, 25:1923-1929.
41. Raue A., Kreutz C., Maiwald T., Klingmüller U., Timmer J. Addressing parameter identifiability by model-based experimentation. IET Syst Biol. 2011, 5:120-130.
42. Rodriguez-Fernandez M., Egea J.A., Banga J.R. Novel metaheuristic for parameter estimation in nonlinear dynamic biological systems. BMC Bioinform. 2006, 7:483.
43. Schindler C., Levy D.E., Decker T. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 2007, 282:20059-20063.
44. Schultz J., Koczan D., Schmitz U., Ibrahim S.M., Pilch D., Landsberg J., Kunz M. Tumor-promoting role of signal transducer and activator of transcription (Stat)1 in late-stage melanoma growth. Clin. Exp. Metastasis 2010, 27:133-140.
45. Shi S., Calhoun H.C., Xia F., Li J., Le L., Li W.X. JAK signaling globally counteracts heterochromatic gene silencing. Nat. Genet. 2006, 38:1071-1076.
46. Soebiyanto R.P., Sreenath S.N., Qu C., Loparo K.A., Bunting K.D. Complex systems biology approach to understanding coordination of JAK-STAT signaling. BioSystems 2007, 90:830-842.
47. Swameye I., Muller T.G., Timmer J., Sandra O., Klingmuller U. Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling. Proc. Natl. Acad. Sci. USA 2003, 100:1028-1033.
48. Valentino L., Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem. Pharmacol. 2006, 71:713-721.
49. Vera J., Balsa-Canto E., Wellstead P., Banga J.R., Wolkenhauer O. Power-Law models of signal transduction pathways. Cell. Signal. 2007, 19:1531-1541.
50. Vera J., Bachmann J., Pfeifer A., Becker V., Hormiga J., Torres Darias N., Timmer J., Klingmuller U., Wolkenhauer O. A systems biology approach to analyse amplification in the JAK2-STAT5 signalling pathway. BMC Syst. Biol. 2008, 2:38.
51. Vera J., Millat T., Kolch W., Wolkenhauer O. Dynamics of receptor and protein transducer homodimerisation. BMC Syst. Biol. 2008, 2:92.
52. Weniger M.A., Melzner I., Menz C.K., Wegener S., Bucur A.J., Dorsch K., Mattfeldt T., Barth T.F., Möller P. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006, 25:2679-2684.
53. Won H.H., Park I., Lee E., Kim J.W., Lee D. Comparative analysis of the JAK/STAT signaling through erythropoietin receptor and thrombopoietin receptor using a systems approach. BMC Bioinform. 2009, 10(Suppl. 1):S53.
54. Yamada S., Shiono S., Joo A., Yoshimura A. Control mechanism of JAK/STAT signal transduction pathway. FEBS Lett. 2003, 534:190-196.
55. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
56. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
57. Zhang Q., Raghunath P.N., Xue L., Majewski M., Carpentieri D.F., Odum N., Morris S., Skorski T., Wasik M.A. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J. Immunol. 2002, 168:466-474.